JANX250516P35000
- 4.50
- -0.20-4.26%
Janux Therapeutics Newsroom
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $90
TD Cowen Maintains Janux Therapeutics(JANX.US) With Buy Rating
Analysts' Top Healthcare Picks: Xenon (XENE), Janux Therapeutics Inc (JANX)
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Janux Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $41 to $200
Janux Therapeutics Is Maintained at Sector Perform by Scotiabank
Janux Therapeutics Analyst Ratings
Wedbush Adjusts Price Target on Janux Therapeutics to $76 From $75, Maintains Outperform Rating
Promising Potential of Janux Therapeutics' Lead Asset and Strategic Plans Justify Buy Rating
Stifel Nicolaus Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TD Cowen Maintains Janux Therapeutics(JANX.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: Janux Therapeutics Inc (JANX), Sun Pharmaceutical Industries Limited (IN:SUNPHARMA)
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $105
Buy Rating for Janux Therapeutics Amidst Competitive Landscape and Advancements in Masked T-cell Engagers
LifeSci Capital Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $100
Janux Therapeutics Price Target Maintained With a $200.00/Share by Cantor Fitzgerald
Janux Therapeutics Analyst Ratings
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100